

Michele Ghidini

List of Publications by Citations

Source: <https://exaly.com/author-pdf/207902/michele-ghidini-publications-by-citations.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

131
papers

2,711
citations

27
h-index

48
g-index

165
ext. papers

3,828
ext. citations

4.5
avg, IF

5.42
L-index

#	Paper	IF	Citations
131	Prognostic Survival Associated With Left-Sided vs Right-Sided Colon Cancer: A Systematic Review and Meta-analysis. <i>JAMA Oncology</i> , 2017 , 3, 211-219	13.4	380
130	Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , 2018 , 19, 1437-1448	21.7	210
129	Effect of Pathologic Tumor Response and Nodal Status on Survival in the Medical Research Council Adjuvant Gastric Infusional Chemotherapy Trial. <i>Journal of Clinical Oncology</i> , 2016 , 34, 2721-7	2.2	144
128	Total Neoadjuvant Therapy in Rectal Cancer: A Systematic Review and Meta-analysis of Treatment Outcomes. <i>Annals of Surgery</i> , 2020 , 271, 440-448	7.8	106
127	FOLFOXIRI Plus Bevacizumab as Conversion Therapy for Patients With Initially Unresectable Metastatic Colorectal Cancer: A Systematic Review and Pooled Analysis. <i>JAMA Oncology</i> , 2017 , 3, e170278	13.4	96
126	1696P Incidence of influenza-like illness (ILI) in cancer patients during COVID-19: The ONCOVID prospective observational study. <i>Annals of Oncology</i> , 2020 , 31, S1001	10.3	78
125	Association of Steroids use with Survival in Patients Treated with Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis. <i>Cancers</i> , 2020 , 12,	6.6	73
124	The efficacy of lapatinib and capecitabine in HER-2 positive breast cancer with brain metastases: A systematic review and pooled analysis. <i>European Journal of Cancer</i> , 2017 , 84, 141-148	7.5	64
123	MicroRNAs (miRNAs) and Long Non-Coding RNAs (lncRNAs) as New Tools for Cancer Therapy: First Steps from Bench to Bedside. <i>Targeted Oncology</i> , 2020 , 15, 261-278	5	63
122	Tumor regression grade and survival after neoadjuvant treatment in gastro-esophageal cancer: A meta-analysis of 17 published studies. <i>European Journal of Surgical Oncology</i> , 2017 , 43, 1607-1616	3.6	61
121	The sexist behaviour of immune checkpoint inhibitors in cancer therapy?. <i>Oncotarget</i> , 2017 , 8, 99336-99346	3.6	55
120	Comparative Effectiveness of Gemcitabine plus Nab-Paclitaxel and FOLFIRINOX in the First-Line Setting of Metastatic Pancreatic Cancer: A Systematic Review and Meta-Analysis. <i>Cancers</i> , 2019 , 11,	6.6	45
119	A randomized phase II trial of two different 4-drug combinations in advanced pancreatic adenocarcinoma: cisplatin, capecitabine, gemcitabine plus either epirubicin or docetaxel (PEXG or PDXG regimen). <i>Cancer Chemotherapy and Pharmacology</i> , 2012 , 69, 115-23	3.5	42
118	Clinical and pathological characterization of HER2 mutations in human breast cancer: a systematic review of the literature. <i>Breast Cancer Research and Treatment</i> , 2017 , 166, 339-349	4.4	42
117	Prognostic Role of Primary Tumor Location in Non-Metastatic Gastric Cancer: A Systematic Review and Meta-Analysis of 50 Studies. <i>Annals of Surgical Oncology</i> , 2017 , 24, 2655-2668	3.1	37
116	Clinical development of mTor inhibitors for renal cancer. <i>Expert Opinion on Investigational Drugs</i> , 2017 , 26, 1229-1237	5.9	37
115	Use of Antibiotics and Risk of Cancer: A Systematic Review and Meta-Analysis of Observational Studies. <i>Cancers</i> , 2019 , 11,	6.6	36

114	Association between DNA-repair polymorphisms and survival in pancreatic cancer patients treated with combination chemotherapy. <i>Pharmacogenomics</i> , 2011 , 12, 1641-52	2.6	36
113	Immune-related Adverse Events and Survival in Solid Tumors Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis. <i>Journal of Immunotherapy</i> , 2020 , 43, 1-7	5	36
112	Characterisation of the immune-related transcriptome in resected biliary tract cancers. <i>European Journal of Cancer</i> , 2017 , 86, 158-165	7.5	34
111	Targeting Immune-Related Biological Processes in Solid Tumors: We do Need Biomarkers. <i>International Journal of Molecular Sciences</i> , 2019 , 20,	6.3	33
110	Adjuvant chemotherapy for resected biliary tract cancers: a systematic review and meta-analysis. <i>Hpb</i> , 2017 , 19, 741-748	3.8	33
109	Estimating 12-week death probability in patients with refractory metastatic colorectal cancer: the Colon Life nomogram. <i>Annals of Oncology</i> , 2017 , 28, 555-561	10.3	32
108	Microsatellite Instability and Survival in Stage II Colorectal Cancer: A Systematic Review and Meta-analysis. <i>Anticancer Research</i> , 2019 , 39, 6431-6441	2.3	30
107	Non-Coding RNAs in Primary Liver Cancer. <i>Frontiers in Medicine</i> , 2015 , 2, 36	4.9	29
106	Association of Obesity With Survival Outcomes in Patients With Cancer: A Systematic Review and Meta-analysis. <i>JAMA Network Open</i> , 2021 , 4, e213520	10.4	29
105	Outcomes Following Immune Checkpoint Inhibitor Treatment of Patients With Microsatellite Instability-High Cancers: A Systematic Review and Meta-analysis. <i>JAMA Oncology</i> , 2020 , 6, 1068-1071	13.4	28
104	Immune-related Adverse Events of Pembrolizumab in a Large Real-world Cohort of Patients With NSCLC With a PD-L1 Expression $\geq 50\%$ and Their Relationship With Clinical Outcomes. <i>Clinical Lung Cancer</i> , 2020 , 21, 498-508.e2	4.9	27
103	Biliary tract cancer: current challenges and future prospects. <i>Cancer Management and Research</i> , 2019 , 11, 379-388	3.6	27
102	KRAS mutation in lung metastases from colorectal cancer: prognostic implications. <i>Cancer Medicine</i> , 2016 , 5, 256-64	4.8	26
101	Timing of Adjuvant Chemotherapy and Survival in Colorectal, Gastric, and Pancreatic Cancer. A Systematic Review and Meta-Analysis. <i>Cancers</i> , 2019 , 11,	6.6	25
100	Clinical and Molecular Predictors of PD-L1 Expression in Non-Small-Cell Lung Cancer: Systematic Review and Meta-analysis. <i>Clinical Lung Cancer</i> , 2018 , 19, 315-322	4.9	25
99	Adjuvant radiotherapy for Merkel cell carcinoma: A systematic review and meta-analysis. <i>Radiotherapy and Oncology</i> , 2019 , 134, 211-219	5.3	24
98	A new nomogram for estimating survival in patients with brain metastases secondary to colorectal cancer. <i>Radiotherapy and Oncology</i> , 2015 , 117, 315-21	5.3	24
97	Different Toxicity of Cetuximab and Panitumumab in Metastatic Colorectal Cancer Treatment: A Systematic Review and Meta-Analysis. <i>Oncology</i> , 2018 , 94, 191-199	3.6	23

96	Neoadjuvant chemoradiotherapy or chemotherapy for gastroesophageal junction adenocarcinoma: A systematic review and meta-analysis. <i>Gastric Cancer</i> , 2019 , 22, 245-254	7.6	22
95	Prognosis of elderly gastric cancer patients after surgery: a nomogram to predict survival. <i>Medical Oncology</i> , 2018 , 35, 111	3.7	21
94	Late immune-related adverse events in long-term responders to PD-1/PD-L1 checkpoint inhibitors: A multicentre study. <i>European Journal of Cancer</i> , 2020 , 134, 19-28	7.5	21
93	Modulation of Biliary Cancer Chemo-Resistance Through MicroRNA-Mediated Rewiring of the Expansion of CD133+ Cells. <i>Hepatology</i> , 2020 , 72, 982-996	11.2	21
92	Combination of radiotherapy and immunotherapy for brain metastases: A systematic review and meta-analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2019 , 144, 102830	7	21
91	Outcome of head compared to body and tail pancreatic cancer: a systematic review and meta-analysis of 93 studies. <i>Journal of Gastrointestinal Oncology</i> , 2019 , 10, 259-269	2.8	20
90	Association of CDX2 Expression With Survival in Early Colorectal Cancer: A Systematic Review and Meta-analysis. <i>Clinical Colorectal Cancer</i> , 2018 , 17, 97-103	3.8	20
89	MicroRNA 193b-3p as a predictive biomarker of chronic kidney disease in patients undergoing radical nephrectomy for renal cell carcinoma. <i>British Journal of Cancer</i> , 2016 , 115, 1343-1350	8.7	20
88	Coronavirus infection and immune system: An insight of COVID-19 in cancer patients. <i>Critical Reviews in Oncology/Hematology</i> , 2020 , 153, 103059	7	18
87	The Agnostic Role of Site of Metastasis in Predicting Outcomes in Cancer Patients Treated with Immunotherapy. <i>Vaccines</i> , 2020 , 8,	5.3	16
86	Surgery or Locoregional Approaches for Hepatic Oligometastatic Pancreatic Cancer: Myth, Hope, or Reality?. <i>Cancers</i> , 2019 , 11,	6.6	16
85	Right Versus Left Colon Cancer: Resectable and Metastatic Disease. <i>Current Treatment Options in Oncology</i> , 2018 , 19, 31	5.4	16
84	Developing a risk assessment score for patients with cancer during the coronavirus disease 2019 pandemic. <i>European Journal of Cancer</i> , 2020 , 135, 47-50	7.5	15
83	Strategies for Increasing the Effectiveness of Aromatase Inhibitors in Locally Advanced Breast Cancer: An Evidence-Based Review on Current Options. <i>Cancer Management and Research</i> , 2020 , 12, 675-686	3.6	14
82	Targeted therapies in gastric cancer treatment: where we are and where we are going. <i>Investigational New Drugs</i> , 2016 , 34, 378-93	4.3	14
81	Salvage therapy with mitomycin and ifosfamide in patients with gemcitabine-resistant metastatic pancreatic cancer: a phase II trial. <i>Chemotherapy</i> , 2011 , 57, 156-61	3.2	14
80	Sequence variation in mature microRNA-608 and benefit from neo-adjuvant treatment in locally advanced rectal cancer patients. <i>Carcinogenesis</i> , 2016 , 37, 852-7	4.6	13
79	Overview of different available chemotherapy regimens combined with radiotherapy for the neoadjuvant and definitive treatment of esophageal cancer. <i>Expert Review of Clinical Pharmacology</i> , 2017 , 10, 649-660	3.8	11

78	Clinical outcome and molecular characterization of brain metastases from esophageal and gastric cancer: a systematic review. <i>Medical Oncology</i> , 2017 , 34, 62	3.7	11
77	Survival of Patients Treated with Antibiotics and Immunotherapy for Cancer: A Systematic Review and Meta-Analysis. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	11
76	A Review of Clinical Practice Guidelines and Treatment Recommendations for Cancer Care in the COVID-19 Pandemic. <i>Cancers</i> , 2020 , 12,	6.6	11
75	Evaluation of Second-line Anti-VEGF after First-line Anti-EGFR Based Therapy in RAS Wild-Type Metastatic Colorectal Cancer: The Multicenter "SLAVE" Study. <i>Cancers</i> , 2020 , 12,	6.6	10
74	Integrating Biological Advances Into the Clinical Management of Breast Cancer Related Lymphedema. <i>Frontiers in Oncology</i> , 2020 , 10, 422	5.3	10
73	Impact of Use of Gastric-Acid Suppressants and Oral Anti-Cancer Agents on Survival Outcomes: A Systematic Review and Meta-Analysis. <i>Cancers</i> , 2020 , 12,	6.6	10
72	Practical review for diagnosis and clinical management of perihilar cholangiocarcinoma. <i>World Journal of Gastroenterology</i> , 2020 , 26, 3542-3561	5.6	10
71	Targeting KRAS in Solid Tumors: Current Challenges and Future Opportunities of Novel KRAS Inhibitors. <i>Pharmaceutics</i> , 2021 , 13,	6.4	10
70	Health-related quality of life associated with trifluridine/tipiracil in heavily pretreated metastatic gastric cancer: results from TAGS. <i>Gastric Cancer</i> , 2020 , 23, 689-698	7.6	9
69	Prognostic factors associated with survival in a large cohort of gastric cancer patients resected over a decade at a single Italian center: the Cremona experience. <i>Clinical and Translational Oncology</i> , 2020 , 22, 1004-1012	3.6	9
68	Syndrome of inappropriate anti-diuretic hormone secretion in cancer patients: results of the first multicenter Italian study. <i>Therapeutic Advances in Medical Oncology</i> , 2019 , 11, 1758835919877725	5.4	8
67	Immune-Based Therapies and the Role of Microsatellite Instability in Pancreatic Cancer. <i>Genes</i> , 2020 , 12,	4.2	8
66	IDH Signalling Pathway in Cholangiocarcinoma: From Biological Rationale to Therapeutic Targeting. <i>Cancers</i> , 2020 , 12,	6.6	8
65	Efficacy and Safety of Trifluridine/Tipiracil Treatment in Patients With Metastatic Gastric Cancer Who Had Undergone Gastrectomy: Subgroup Analyses of a Randomized Clinical Trial. <i>JAMA Oncology</i> , 2020 , 6, e193531	13.4	7
64	Survival of Colorectal Cancer Patients With Diabetes Mellitus: A Meta-Analysis. <i>Canadian Journal of Diabetes</i> , 2021 , 45, 186-197.e2	2.1	7
63	Impact of tumor site on the prognosis of small bowel adenocarcinoma. <i>Tumori</i> , 2019 , 105, 524-528	1.7	6
62	Weight loss and body mass index in advanced gastric cancer patients treated with second-line ramucirumab: a real-life multicentre study. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019 , 145, 2365-2373	4.9	6
61	Vinorelbine in BRAF V600E mutated metastatic colorectal cancer: a prospective multicentre phase II clinical study. <i>ESMO Open</i> , 2017 , 2, e000241	6	6

60	Impact of BMI on Survival Outcomes of Immunotherapy in Solid Tumors: A Systematic Review. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	6
59	New developments in the treatment of chemotherapy-induced neutropenia: focus on balugrastim. <i>Therapeutics and Clinical Risk Management</i> , 2016 , 12, 1009-15	2.9	6
58	The Role and Expression of Angiogenesis-Related miRNAs in Gastric Cancer. <i>Biology</i> , 2021 , 10,	4.9	6
57	Risk of second primary tumors in GIST survivors: A systematic review and meta-analysis. <i>Surgical Oncology</i> , 2019 , 29, 64-70	2.5	5
56	Renal Function Assessment Gap in Clinical Practice: An Awkward Truth. <i>Kidney and Blood Pressure Research</i> , 2020 , 45, 166-179	3.1	5
55	A systematic review of salvage therapies in refractory metastatic colorectal cancer. <i>International Journal of Colorectal Disease</i> , 2020 , 35, 783-794	3	5
54	First-line dose-dense chemotherapy with docetaxel, cisplatin, folinic acid and 5-fluorouracil (DCF) plus panitumumab in patients with locally advanced or metastatic cancer of the stomach or gastroesophageal junction: final results and biomarker analysis from an Italian oncology group for clinical research (GOIRC) phase II study. <i>Oncotarget</i> , 2017 , 8, 111795-111806	3.3	5
53	Obesity paradox in patients with cancer: A systematic review and meta-analysis of 6,320,365 patients		5
52	Circulating Tumour DNAs and Non-Coding RNAs as Liquid Biopsies for the Management of Colorectal Cancer Patients. <i>Gastrointestinal Disorders</i> , 2020 , 2, 212-235	0.8	5
51	Immune-Checkpoint Inhibitors in Platinum-Resistant Ovarian Cancer. <i>Cancers</i> , 2021 , 13,	6.6	5
50	Overall survival results from a phase III trial of trifluridine/tipiracil versus placebo in patients with metastatic gastric cancer refractory to standard therapies (TAGS). <i>Annals of Oncology</i> , 2018 , 29, v122	10.3	5
49	Lactobacillus Kefiri LKF01 (Kefibios) for Prevention of Diarrhoea in Cancer Patients Treated with Chemotherapy: A Prospective Study. <i>Nutrients</i> , 2021 , 13,	6.7	5
48	Adjuvant chemotherapy in patients with rectal cancer achieving pathologic complete response after neoadjuvant chemoradiation and surgery. <i>European Journal of Cancer</i> , 2019 , 108, 97-99	7.5	4
47	Epidemiological, clinical and pathological characteristics of gastric neoplasms in the province of Cremona: the experience of the first population-based specialized gastric cancer registry in Italy. <i>BMC Cancer</i> , 2019 , 19, 212	4.8	4
46	The treatment paradigm of right-sided metastatic colon cancer: harboring BRAF mutation makes the difference. <i>International Journal of Colorectal Disease</i> , 2020 , 35, 1513-1527	3	4
45	Pharmacotherapeutic advances with anaplastic lymphoma kinase inhibitors for the treatment of non-small cell lung cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2020 , 21, 931-940	4	4
44	MicroRNAs as Mediators of Resistance Mechanisms to Small-Molecule Tyrosine Kinase Inhibitors in Solid Tumours. <i>Targeted Oncology</i> , 2018 , 13, 423-436	5	4
43	Major innovations and clinical applications of disodium-levofolinate: a review of available preclinical and clinical data. <i>Therapeutic Advances in Medical Oncology</i> , 2019 , 11, 1758835919853954	5.4	4

42	Disease-free survival is not a surrogate endpoint for overall survival in adjuvant trials of pancreatic cancer: a systematic review of randomized trials. <i>Hpb</i> , 2017 , 19, 944-950	3.8	4
41	Modified schedules of DCF chemotherapy for advanced gastric cancer: a systematic review of efficacy and toxicity. <i>Anti-Cancer Drugs</i> , 2017 , 28, 133-141	2.4	4
40	Clinicians' Attitude to Doublet Plus Anti-EGFR Versus Triplet Plus Bevacizumab as First-line Treatment in Left-Sided RAS and BRAF Wild-Type Metastatic Colorectal Cancer Patients: A Multicenter, "Real-Life", Case-Control Study. <i>Clinical Colorectal Cancer</i> , 2021 ,	3.8	4
39	Triage process for the assessment of coronavirus disease 2019-positive patients with cancer: The ONCOVID prospective study. <i>Cancer</i> , 2021 , 127, 1091-1101	6.4	4
38	Effects of hypertension on cancer survival: A meta-analysis. <i>European Journal of Clinical Investigation</i> , 2021 , 51, e13493	4.6	4
37	Analysis of symptoms and functional HRQoL scales in TAGS, a phase III trial of trifluridine/tipiracil (FTD/TPI) in metastatic gastric cancer (mGC).. <i>Journal of Clinical Oncology</i> , 2019 , 37, 4043-4043	2.2	3
36	Post-Induction Management in Patients With Left-Sided and Wild-Type Metastatic Colorectal Cancer Treated With First-Line Anti-EGFR-Based Doublet Regimens: A Multicentre Study. <i>Frontiers in Oncology</i> , 2021 , 11, 712053	5.3	3
35	Evaluation of Prognostic Factors for Survival in Transverse Colon Cancer. <i>Cancers</i> , 2020 , 12,	6.6	3
34	How to Best Exploit Immunotherapeutics in Advanced Gastric Cancer: Between Biomarkers and Novel Cell-Based Approaches. <i>Journal of Clinical Medicine</i> , 2021 , 10,	5.1	3
33	PD-1/PD-L1 checkpoint inhibitors during late stages of life: an ad-hoc analysis from a large multicenter cohort. <i>Journal of Translational Medicine</i> , 2021 , 19, 270	8.5	3
32	Gemcitabine/Nab-Paclitaxel versus FOLFIRINOX in Locally Advanced Pancreatic Cancer: A European Multicenter Study. <i>Cancers</i> , 2021 , 13,	6.6	3
31	Red blood cell transfusions and the survival in patients with cancer undergoing curative surgery: a systematic review and meta-analysis. <i>Surgery Today</i> , 2021 , 51, 1535-1557	3	3
30	What Medical Oncologist Residents Think about the Italian Speciality Schools: A Survey of the Italian Association of Medical Oncology (AIOM) on Educational, Clinical and Research Activities. <i>PLoS ONE</i> , 2016 , 11, e0159146	3.7	2
29	Nivolumab plus ipilimumab for the first-line treatment of metastatic NSCLC. <i>Expert Review of Anticancer Therapy</i> , 2021 , 21, 705-713	3.5	2
28	The Emergence of Immune-checkpoint Inhibitors in Colorectal Cancer Therapy. <i>Current Drug Targets</i> , 2021 , 22, 1021-1033	3	2
27	Efficacy and safety of trifluridine/tipiracil (FTD/TPI) in patients (pts) with metastatic gastric cancer (mGC) with or without prior gastrectomy: Results from a phase III study (TAGS).. <i>Journal of Clinical Oncology</i> , 2019 , 37, 3-3	2.2	1
26	A multicenter study of skin toxicity management in patients with left-sided, RAS/BRAF wild-type metastatic colorectal cancer treated with first-line anti-EGFR-based doublet regimen: is there room for improvement?. <i>Supportive Care in Cancer</i> , 2021 , 30, 2455	3.9	1
25	Letter of response to comments on: Developing a risk assessment score for patients with cancer during COVID-19 pandemic: A war on two fronts. <i>European Journal of Cancer</i> , 2020 , 140, 161-162	7.5	1

24	The Appropriateness of Invasive Ventilation in COVID-19 Positive Cancer Patients: Proposal of a New Prognostic Score. <i>Viruses</i> , 2021 , 13,	6.2	1
23	Tocilizumab as treatment for COVID-19: A systematic review and meta-analysis. <i>World Journal of Methodology</i> , 2021 , 11, 95-109	1.2	1
22	Population-Based Long-term Cardiac-Specific Mortality Among Patients With Major Gastrointestinal Cancers. <i>JAMA Network Open</i> , 2021 , 4, e2112049	10.4	1
21	Longitudinal Circulating Levels of miR-23b-3p, miR-126-3p and lncRNA GAS5 in HCC Patients Treated with Sorafenib. <i>Biomedicines</i> , 2021 , 9,	4.8	1
20	Micropapillary Bladder Cancer Metastatic to the Breast: A Case Report and Brief Literature Review. <i>In Vivo</i> , 2021 , 35, 453-459	2.3	1
19	Clinical outcomes of NSCLC patients experiencing early immune-related adverse events to PD-1/PD-L1 checkpoint inhibitors leading to treatment discontinuation. <i>Cancer Immunology, Immunotherapy</i> , 2021 , 1	7.4	1
18	Metabolic disorders and the risk of cholangiocarcinoma. <i>Expert Review of Gastroenterology and Hepatology</i> , 2021 , 15, 999-1007	4.2	1
17	Total neoadjuvant therapy for initially inoperable pancreatic cancer: A systematic review of phase 2-3 studies. <i>Radiotherapy and Oncology</i> , 2021 , 164, 13-19	5.3	1
16	High familial burden of cancer correlates with improved outcome from immunotherapy in patients with NSCLC independent of somatic DNA damage response gene status.. <i>Journal of Hematology and Oncology</i> , 2022 , 15, 9	22.4	0
15	Survival benefit with adjuvant chemotherapy in stage III microsatellite-high/deficient mismatch repair colon cancer: a systematic review and meta-analysis.. <i>Scientific Reports</i> , 2022 , 12, 1055	4.9	0
14	MicroRNAs as Diagnostic Tools in Hepatocellular Carcinoma. <i>Gastrointestinal Disorders</i> , 2021 , 3, 237-246	0.8	0
13	Advances in the pharmacological management of neutropenia in solid tumors: the advent of biosimilars. <i>Expert Opinion on Pharmacotherapy</i> , 2021 , 22, 857-865	4	0
12	ctDNA analysis in the personalized clinical management of gastroesophageal adenocarcinoma: turning hope into reality. <i>Future Oncology</i> , 2021 , 17, 4607-4618	3.6	0
11	Nanomedicine for the Delivery of RNA in Cancer. <i>Cancers</i> , 2022 , 14, 2677	6.6	0
10	Prognostic factors associated with survival and recurrence in resectable gastric cancer: Retrospective analysis of 379 patients operated at Cremona Hospital from 2007 to 2016.. <i>Journal of Clinical Oncology</i> , 2018 , 36, e16079-e16079	2.2	
9	Immune-related adverse events (irAEs) and survival in solid tumors treated with immune checkpoint inhibitors (ICIs): A systematic review and meta-analysis.. <i>Journal of Clinical Oncology</i> , 2019 , 37, e14130-e14130	2.2	
8	Is there a correlation between clinic-pathological features, MSI, PD-L1 and survival outcomes in resected gastric cancer? Looking for optimal biomarkers.. <i>Journal of Clinical Oncology</i> , 2019 , 37, e15566-e15566	2.2	
7	Circulating-free DNA analysis from long-term surviving metastatic colorectal cancer patients undergoing surgery for resectable disease.. <i>Journal of Clinical Oncology</i> , 2019 , 37, e14545-e14545	2.2	

- 6 Clinical impact of neutropenia and febrile neutropenia in mCRC pts treated with FOLFOXIRI/bevacizumab (bev): A pooled analysis of TRIBE and TRIBE2 studies.. *Journal of Clinical Oncology*, **2019**, 37, 11591-11591 2.2
- 5 Prognostic factors associated with survival and recurrence in resectable gastroesophageal adenocarcinoma: retrospective analysis of 497 patients operated at two Italian centers.. *Journal of Clinical Oncology*, **2017**, 35, e15588-e15588 2.2
- 4 Presence of bone metastases(BM) at diagnosis is associated with poor prognosis and coagulation disorders (CD) in patients (pts) with advanced gastric cancer (AGC).. *Journal of Clinical Oncology*, **2017**, 35, e15538-e15538 2.2
- 3 Circulating Tumor DNA as a Biomarker for Outcomes Prediction in Colorectal Cancer Patients. *Current Drug Targets*, **2021**, 22, 1010-1020 3
- 2 Development and Multicentre Validation of the Modena Score to Predict Survival in Advanced Biliary Cancers Undergoing Second-Line Chemotherapy.. *Cancer Management and Research*, **2022**, 14, 983-993 3.6
- 1 Renal Function Outcomes in Metastatic Non-Small-Cell Lung Carcinoma Patients Treated with Chemotherapy or Immune Checkpoint Inhibitors: An Unexpected Scenario. *Vaccines*, **2022**, 10, 679 5.3